Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Salivary Gland Cancer
NCT03729297Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in salivary gland cancer (SGC), sponsored by Radboud University Medical Center. Primary endpoint: Overall Response Rate. Started Sep 2018; status: terminated.
02
Drugs
cabozantinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT03729297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729297.